Therapy Areas: Oncology
Vial adds Dr Neeraj Agarwal to scientific advisor for Oncology CRO
8 August 2022 -

United States-based contract research organisation Vial announced on Sunday that it has named Dr Neeraj Agarwal as scientific advisor for the company's Oncology CRO.

Dr Agarwal is a genitourinary cancer specialist and has been the overall study chair of multiple Phase I, Phase II, and Phase III trials and serves as a steering committee member of numerous other studies. He was named senior director of Clinical Research Innovation at the Huntsman Cancer Institute, University of Utah, where he holds multiple other leadership positions. He is a consultant to the US FDA's Oncology Drug Advisory Committee (ODAC) and heads early therapeutics in the SWOG genitourinary cancers committee.

Dr Agarwal said: "Over the last two decades, the entire process of conducting clinical trials has exponentially grown cumbersome. It is critical for this process to become more efficient to improve administrative work for the investigating teams, make it easier for our patients to enrol, improve the accrual timeline, and expedite and decrease the cost of drug development."